GSK 299423

GSK 299423
Names
	IUPAC name 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile
Identifiers
CAS Number	1352149-24-6 ;
3D model (JSmol)	Interactive image;
ChemSpider	24751852 ;
UNII	2Q0G81H7FK ;
	InChI InChI=1S/C25H27N5O2S/c1-31-20-2-3-23-22(11-20)21(17(12-26)13-29-23)6-9-30-7-4-18(5-8-30)27-14-19-10-25-24(15-28-19)32-16-33-25/h2-3,10-11,13,15,18,27H,4-9,14,16H2,1H3 Key: NKXJSCXEAVZSMF-UHFFFAOYSA-N ;
	SMILES COc1ccc2c(c1)c(c(cn2)C#N)CCN3CCC(CC3)NCc4cc5c(cn4)OCS5;
Properties
Chemical formula	C25H27N5O2S
Molar mass	461.58 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

3D protein map of GSK 299423 (yellow) in complex with Staphylococcus aureus DNA gyrase (teal) and a DNA fragment (orange). From PDB: 2xcs.

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.^[1]^[2]^[3]

No animal studies have been reported. No application has been made for human clinical trials.

References

↑ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010
↑ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs'" Daily Finance, August 6, 2010
↑ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. doi:10.1038/nature09197. PMID 20686482. (primary source)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010

[2] Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs'" Daily Finance, August 6, 2010

[Bax2010-3] Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. doi:10.1038/nature09197. PMID 20686482. (primary source)